Month: August 2020

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (“Amerigo” or the “Company”) (TSX: ARG) is pleased to announce the appointment of Carmen Amezquita, CPA, CA as Chief Financial Officer, effective August 1, 2020.Carmen has served as the Chief Financial Officer and Corporate Controller for mining companies with both producing mines and exploration properties located in Latin America. Previous to that, she worked in the audit and assurance group at PricewaterhouseCoopers.Carmen is fluent in Spanish and received her Chartered Accountant designation in 2010. She holds a Bachelor of Arts degree from the University of British Columbia (“UBC”) and has a Diploma in Accounting from Sauder School of Business at UBC.About Amerigo and Minera Valle Central (“MVC”)Amerigo Resources Ltd....

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Lupaka Gold Corp. (“Lupaka Gold” or the “Company“) (TSX-V: LPK, FRA: LQP) reports that it has entered into an Arbitration Funding Agreement with Bench Walk Advisors (“BWA”) to support the Company’s arbitration claim against the Republic of Peru under the 2009 Canada-Peru Free Trade Agreement (“FTA”; see also the Company’s news release of 16 December 2019).The Agreement allows for up to USD$4.1 million to support the arbitration and related costs. All monies to be advanced by BWA are non-recourse and are only repayable upon completion of a successful claim where monies are recovered. As such, the financing is non-dilutive to current Lupaka shareholders. Precise terms of the Arbitration Funding Agreement (other than those set out herein) are confidential.The...

DENVER, Aug. 04, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine”), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform.Mindleap™ is working towards contributing to the evolution of mental health and enabling the mass adoption of mental health treatments across the world. In order to expand access to world-class mental health solutions, Mindleap is developing new “30-day transformation” programs that will be offered as in-app purchases on the platform this fall.The new offerings will include comprehensive addiction, psychedelic integration, and holistic wellness programs designed to empower users...

ROBIT PLC        PRESS RELEASE        4 AUGUST 2020 AT 2.30 P.M.                     ROBIT INITIATES EMPLOYEE COOPERATION NEGOTIATIONS IN FINLANDRobit initiates employee cooperation negotiations in its subsidiary, Robit Finland Ltd, in relation to possible changes and actions to ensure and strengthen the company’s long-term profitability and cash flow. Robit disclosed the temporary lay-offs carried out in its Finnish units with a press release on 2 April 2020 as a part of preparing for COVID-19 situation.”In the present business environment, we are obliged to carry out also permanent cost savings based on profitability reasons, preparing at the same time for a longer duration of COVID-19 effects,” states Group CEO, Tommi Lehtonen.Employee cooperation negotiations cover senior salaried personnel of Robit Finland Ltd. Negotiations may result...

ROBIT OYJ        LEHDISTÖTIEDOTE        4.8.2020 KLO 14.30ROBIT KÄYNNISTÄÄ YT-NEUVOTTELUT SUOMESSARobit käynnistää tytäryhtiössään, Robit Finland Oy:ssä yhteistoimintaneuvottelut mahdollisista muutoksista ja toimenpiteistä, joiden tarkoituksena on yrityksen kannattavuuden ja kassavirran varmistaminen ja vahvistaminen pitkällä aikavälillä. Robit ilmoitti Suomen yksiköissä toteutettavista lomautuksista lehdistötiedotteella 2.4.2020 johtuen varautumisesta COVID-19-tilanteeseen.”Nykyisessä toimintaympäristössä joudumme tekemään myös pysyviä kustannussäästöjä kannattavuussyistä varautuen samalla pidempään COVID-19-vaikutusaikaan,” toteaa toimitusjohtaja, Tommi Lehtonen.Neuvotteluiden kohteena ovat kaikki Robit Finland Oy:n ylempien toimihenkilöiden henkilöstöryhmään kuuluvat työntekijät. Neuvottelut voivat johtaa työvoiman pysyvään vähentämiseen...

sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and overPARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is March 22, 2021.The sNDA is based on the positive data from the Phase 3 PLAY study of EXPAREL infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with...

CELEBRATION, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020.Conference Call Information:(866) 395-2480 (U.S.)(678) 509-7538 (international)Conference ID: 5176398 An audio webcast with slide presentation will be accessible via the Investor Relations section of the Company’s website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 5:30 p.m. ET, on August 12, 2020.About KemPharm:KemPharm is a specialty pharmaceutical company...

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual events is pleased to announce it has been selected to provide the InfernoAR platform, ScreenAR, and event design services for CREVOLUTION 2020 from ICM Credit in Mexico November 10 – 12, 2020. The initial value of the contract is $90,000 with the potential for additional revenue through the sale of augmented reality booths, and ‘ScreenAR’ services.Luis Eduardo Perez, President, ICM Credit comments, “Crevolution is the most disruptive event in the global financial industry, when moving to a digital environment, we had the need to maintain that innovative spirit in...

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise...

WALTHAM, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for ELX-02 for the treatment of Cystic Fibrosis.The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S. Orphan-drug designation qualifies Eloxx for certain benefits, including seven years of market exclusivity upon regulatory approval if received, exemption...